<DOC>
	<DOCNO>NCT00657254</DOCNO>
	<brief_summary>The study design allow continuation treatment Sorafenib single agent patient participate previous Sorafenib study reach designate end-date , opinion Investigator Sponsor , still benefit treatment .</brief_summary>
	<brief_title>Extension Program Bay 43-9006</brief_title>
	<detailed_description />
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients participate previous sorafenib study complete , meet withdrawal criterion previous study , opinion investigator sponsor still benefit treatment . Exclusion Criteria : The current cardiovascular situation patient carefully reevaluate investigator sponsor inform decision inclusion make . Substance abuse , medical , psychological social condition may interfere patient 's participation study evaluation study result . Known suspect allergy investigational agent . Any condition unstable could jeopardise safety patient his/her compliance study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Extension</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Survival</keyword>
</DOC>